Select Publications

Douillard JY et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: A randomized, open-label Phase III study (INTEREST). 12th World Conference
on Lung Cancer 2007;Abstract PRS-02.

Heymach JV et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007a;25(27):4270-7. Abstract

Heymach J et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small
cell lung cancer (NSCLC). Proc ASCO 2007b;Abstract 7544.

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Shepherd FA et al. Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Canada. Proc ASCO 2007;Abstract 7571.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS

Mark G Kris, MD
- Select publications

Roman Perez-Soler, MD
- Select publications

Julie R Brahmer, MD
- Select publications

Philip Bonomi, MD
- Select publications

 

Lung Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office